Gut Bacteria Compound Could Slow Alzheimer’s Disease Progression

A compound produced by gut bacteria, known as propionate, shows potential in reducing inflammation and plaque buildup, possibly slowing the progression of Alzheimer’s disease. This research underscores the pivotal role of the gut microbiome in neurodegenerative conditions and opens new therapeutic possibilities.
Recent research from Northwestern University highlights the potential of a gut-produced compound to mitigate some effects of Alzheimer’s disease. Alzheimer’s, the leading cause of dementia affecting over 6 million Americans, is expected to see a sharp increase as the population ages. While the connection between gut microbiota and Alzheimer’s pathology has long been suspected, the specific mechanisms remained unclear.
In a groundbreaking study, scientists administered antibiotics to mice engineered to develop Alzheimer’s, observing changes in their gut microbiome. The treatment increased levels of a short-chain fatty acid called propionate, produced by certain bacteria in the gut. Propionate is known to play a significant role in controlling brain inflammation and amyloid plaque formation—both hallmark features of Alzheimer’s.
Further experiments involved adding propionate directly to the mice’s water supply. The results showed reduced markers of neuroinflammation, decreased amyloid plaques, and lower levels of IL-17, a cytokine involved in immune response. Notably, these effects were predominantly observed in male mice, indicating possible sex-related differences.
The research suggests that boosting propionate levels through diet, probiotics, or medication might slow Alzheimer’s progression. Vassar and his team are now exploring how female hormones influence the gut microbiome’s response to such treatments. They also aim to uncover the detailed mechanisms by which propionate reduces inflammation and plaque buildup.
This discovery opens promising therapeutic avenues, where manipulating gut bacteria could become part of Alzheimer’s treatment strategies, potentially delaying or reducing the severity of symptoms. The findings emphasize the importance of the gut microbiome in neurodegenerative disease management and warrant further clinical research.
For more detailed information, visit the original study published in the Journal of Clinical Investigation: [DOI: 10.1172/JCI180826].
Source: MedicalXpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Prenatal PFAS Exposure on Infant Immunity and Long-term Health
This study reveals how prenatal exposure to PFAS chemicals can alter infant immune development, potentially affecting vaccine responses and increasing risks of allergies and autoimmune diseases.
Rising Gabapentin Prescriptions Spotlight Need for Safety Awareness
Gabapentin prescriptions have surged in recent years, highlighting the need for increased awareness of its potential adverse effects and safe prescribing practices.
Malaria Prevention Drug Remains Effective for Babies Despite Resistance in Parasites
Recent research confirms that sulfadoxine-pyrimethamine (SP) continues to protect infants' birth outcomes despite increasing resistance from malaria parasites in Africa, supporting ongoing maternal health strategies.



